Meline David W
Meline David W's purchase track record
Meline David W has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/6/2024 | PACB | $176K | -51.2% | -68.4% | +8.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
HPQ earnings beat followed by stock decline. HP reported earnings that exceeded analysts' expectations, marking a positive surprise for the quarter. Despite the beat, the shares fell more than the broader market, drawing fresh attention to the stock's recent weakness. The price is now near a long‑standing support level around $24.05, a point that has been tested many times.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Moderna faces stock dip amid cancer vaccine news and cash position. Recent articles note that Moderna holds a large cash reserve while advancing a deep cancer pipeline. A Phase 3 trial of its cancer vaccine reported positive results, which could broaden the company's product base. At the same time, the stock has fallen sharply, reflecting broader weakness in biotech and a pause in the recent rally. The decline occurs despite the cash strength and analyst price targets that remain well above current levels.
Transaction History
| PACB | ▲ Buy | Grant | 17,116 | $0 | 6/18/2024 | View on chart |
| HPQ | ▲ Buy | Grant | 7,943 | $0 | 4/22/2024 | View on chart |
| PACB | ▲ Buy | Open Market | 40,000 | $176K | 3/6/2024 | View on chart |
| HPQ | ▲ Buy | Grant | 2,747 | $0 | 11/1/2023 | View on chart |
| MRNA | ▼ Sell | Open Market | 164 | $28K | 8/10/2022 | View on chart |
| MRNA | ▲ Buy | Option Exercise | 348 | $0 | 8/9/2022 | View on chart |
| MRNA | ▼ Sell | Open Market | 156 | $21K | 5/10/2022 | View on chart |
| MRNA | ▲ Buy | Option Exercise | 348 | $47K | 5/9/2022 | View on chart |
| MRNA | ▼ Sell | Open Market | 619 | $98K | 2/10/2022 | View on chart |
| MRNA | ▲ Buy | Option Exercise | 1,392 | $0 | 2/9/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
PACB Pushes HiFi Sequencing for Clinical Growth
Pacific Biosciences is focusing on its HiFi sequencing technology to drive clinical adoption and achieve $40 million in savings. This strategic push aims to address the company's ongoing profitability challenges while targeting long-term growth. The stock recently saw a volume spike and touched its 200-day moving average, reflecting heightened market interest in these operational updates.
PACB Pushes HiFi Sequencing for Clinical Growth. Pacific Biosciences is focusing on its HiFi sequencing technology to drive clinical adoption and achieve $40 million in savings. This strategic push aims to address the company's ongoing profitability challenges while targeting long-term growth. The stock recently saw a volume spike and touched its 200-day moving average, reflecting heightened market interest in these operational updates.